1. Home
  2. KULR vs NKTX Comparison

KULR vs NKTX Comparison

Compare KULR & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KULR Technology Group Inc.

KULR

KULR Technology Group Inc.

HOLD

Current Price

$3.83

Market Cap

176.2M

Sector

Technology

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.86

Market Cap

198.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KULR
NKTX
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.2M
198.2M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
KULR
NKTX
Price
$3.83
$2.86
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
2.7M
479.0K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
$1,274,028.00
N/A
Revenue This Year
$123.93
N/A
Revenue Next Year
$63.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.63
52 Week High
$7.49
$3.65

Technical Indicators

Market Signals
Indicator
KULR
NKTX
Relative Strength Index (RSI) 49.97 52.26
Support Level $2.93 $2.59
Resistance Level $4.47 $3.34
Average True Range (ATR) 0.44 0.22
MACD -0.12 -0.00
Stochastic Oscillator 17.45 60.00

Price Performance

Historical Comparison
KULR
NKTX

About KULR KULR Technology Group Inc.

KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: